New hope for IVF patients: drug may prevent dangerous ovarian overreaction

NCT ID NCT07043322

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two methods to prevent ovarian hyperstimulation syndrome (OHSS), a serious side effect of fertility treatments. About 150 women at high risk for OHSS will receive either cabergoline or a standard 'coasting' procedure. The goal is to see which approach better reduces the occurrence and severity of OHSS.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GYNECOLOGIC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mostafa Bahaa

    RECRUITING

    Damietta, New Damietta, 34518, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.